The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
BSH 2018 | Combination therapies in CLL: ibrutinib and venetoclax
There has been a multitude of novel, exciting therapies within the field of chronic lymphocytic leukemia (CLL), explains Stephen Devereux, FRCP, FRCPath, PhD, of King’s College Hospital NHS Foundation Trust, London, UK. At the British Society for Haematology (BSH) 2018 Annual Scientific Meeting, in Liverpool, UK, Prof. Devereux discusses the CLARITY trial (ISCRTN13751862), exploring a combination of ibrutinib and venetoclax, and the promise that this may in the future result in a curative therapy for certain patients.
